Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $346
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $310 to $346.
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $310 to $346.